DETAILS of an Australian and NZ clinical trial that has found a low-cost version of ketamine is effective for treating severe depression when compared to a placebo, will be released tomorrow.
Apparently, more than one in five people achieved total remission from their symptoms after a month of twice-weekly injections, while a third improved by at least 50%.
Ketamine is used as an anaesthetic for both humans and animals, and it also has a reputation as a 'party drug', but research to be released tomorrow suggests it may be an effective way to help people with hard-to-treat depression.
The study is a collaboration between six academic clinical mood disorder units in Australia and one in New Zealand, and was funded by the Australian National Health and Medical Research Council.
The above article was sent to subscribers in Pharmacy Daily's issue from 13 Jul 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 13 Jul 23
